Lipidio is a development stage biopharma focused on diseases associated with excess body fat.
Meet Lipidio Pharmaceuticals
Why is your company the best option to solve the problem you're solving?
GDD3898, is a topically applied, small molecule drug, for the treatment of diseases associated with excess body fat, such as nonalcoholic steatohepatitis (“NASH”), anti-psychotic drug induced weight gain, as well as orphan indications, such as Prader Willi Syndrome. Its mechanism and our approach is literally unique in the Industry. We have also assembled world leading scientific advisors in metabolic diseases that will be critical to advising Lipidio as we advance our first molecule.
What nuggets of info make you interesting? Why do people care about what you're doing?
While San Diego is certainly one of the most healthy cities in the USA, the prevalence of obesity in US is now almost 40%, affecting over 93 million adults. It not only impacts heart disease and diabetes, but also drives the diseases we are targeting, where there are no approved drugs for any of these indications. The impact of obesity even on Covid 19 severity is now well recognized by the CDC.
BEHIND THE COMPANY
Founder/CEO: J Gordon Foulkes
What inspired you (CEO/Founder) to start/run this company?
I've been building companies for 30 years. This one has a truly unique drug and mechanism that could represent an entirely different way to develop drugs to treat multiple systemic diseases.
What's the best entrepreneurial advice you've received?
Hire people who are better at their job than you could ever be! Never settle for average team members. You only realize who are great Board members when times are hard.